LexaGene Holdings, Inc. CEO Dr Jack Regan joined Proactive's Stephen Gunnion to share the news that the molecular diagnostics company continues to systematically advance its MiQLab System to meet the Food and Drug Administration (FDA) criteria for Emergency Use Authorization (EUA).
The MiQLab System is a first of its kind, point of care diagnostic testing technology.
Regan telling Proactive that the intent of the FDA requirements is to ensure vendors take the necessary steps to get the highest quality product possible out of their specific technology. He said LexaGene has made great progress and completed many of these requirements over the last few months.